Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders

Isabel Pascual-Camps, Pablo Hernández-Martínez, Laura Monje-Fernández, Rosa Dolz-Marco, Roberto Gallego-Pinazo, Lihteh Wu, J Fernando Arévalo, Manuel Díaz-Llopis, Isabel Pascual-Camps, Pablo Hernández-Martínez, Laura Monje-Fernández, Rosa Dolz-Marco, Roberto Gallego-Pinazo, Lihteh Wu, J Fernando Arévalo, Manuel Díaz-Llopis

Abstract

Tumor necrosis factor alpha (TNF-?) is an important pro-inflammatory cytokine associated with a variety of ocular diseases. The currently available TNF-? inhibitors are etanercept, infliximab, adalimumab, golimumab, and certolizumab. Experimental and clinical studies on the intravitreal use of these agents have been reported with etanercept, infliximab, and adalimumab: etanercept has shown limited efficacy in scarce reports; infliximab has been associated with local safety concerns but appears to benefit certain cases; adalimumab has shown no efficacy in cases of age-related macular degeneration (AMD) or diabetic macular edema (DME), but the combination with bevacizumab may be effective in refractory cases of macular diseases. Further preclinical and clinical studies are warranted in order to be able to obtain a more robust conclusion on the use of intravitreal TNF-? inhibitors.

Keywords: Adalimumab; Etanercept; Infliximab; Intravitreal injection; Ocular disorders; Tumor necrosis factor alpha.

References

    1. Noma H, Mimura T, Eguchi S. Association of inflammatory factors with macular edema in branch retinal vein occlusion. JAMA Ophthalmol. 2013;131:160–165. doi: 10.1001/2013.jamaophthalmol.228.
    1. Augustin AJ, Kirchhof J. Inflammation and the pathogenesis of age-related macular degeneration. Expert Opin Ther Targets. 2009;13:641–651. doi: 10.1517/14728220902942322.
    1. Wang Y, Wang VM, Chan CC. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond) 2011;25:127–139. doi: 10.1038/eye.2010.196.
    1. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina. 2007;27:399–413. doi: 10.1097/MAJ.0b013e3180318fbc.
    1. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717–1724. doi: 10.1056/NEJM199606273342607.
    1. Feldmann M, Maini RN. Anti-TNF-a therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163–196. doi: 10.1146/annurev.immunol.19.1.163.
    1. Sfikakis PP, Kollias G. TNF biology in experimental and clinical arthritis. Curr Opin Rheumatol. 2003;15:380–386. doi: 10.1097/00002281-200307000-00003.
    1. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9:271–285. doi: 10.1038/nri2526.
    1. Pulido JS, Pulido JE, Michet CJ, Vile RG. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. Retina. 2010;30:1–5. doi: 10.1097/IAE.0b013e3181cde727.
    1. Modorati G, Miserocchi E. Intravitreal injection therapy in the treatment of noninfectious uveitis. Dev Ophthalmol. 2012;51:110–121. doi: 10.1159/000336471.
    1. Tempest-Roe S, Joshi L, Dick AD, Taylor SR. Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmol. 2013;6(13):39. doi: 10.1186/1471-2415-13-39.
    1. Fauser S, Kalbacher H, Alteheld N, Koizumi K, Krohne TU, Joussen AM. Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch Clin Exp Ophthalmol. 2004;242:582–586. doi: 10.1007/s00417-004-0895-x.
    1. Kivilcim M, Peyman GA, Kazi AA, Dellacroce J, Ghobrial RN, Monzano R. Intravitreal toxicity of high-dose etanercept. J Ocul Pharmacol Ther. 2007;23:57–62. doi: 10.1089/jop.2006.0083.
    1. Tsilimbaris MK, Panagiotoglou TD, Charisis SK, Anastasakis A, Krikonis TS, Christodoulakis E. The use of intravitreal etanercept in diabetic macular oedema. Semin Ophthalmol. 2007;22:75–79. doi: 10.1080/08820530701418243.
    1. Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol. 2007;125:1221–1224. doi: 10.1001/archopht.125.9.1221.
    1. Giansanti F, Ramazzotti M, Vannozzi L, Rapizzi E, Fiore T, Iaccheri B, Degl' Innocenti D, Moncini D, Menchini U. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci. 2008;49:1151–1156. doi: 10.1167/iovs.07-0932.
    1. Theodossiadis PG, Liarakos VS, Sfikakis PP, Charonis A, Agrogiannis G, Kavantzas N, Vergados IA. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2009;247:273–281. doi: 10.1007/s00417-008-0967-4.
    1. Hosseini H, Safaei A, Khalili MR, Nowroozizadeh B, Eghtedari M, Farvardin M, Nowroozizadeh S, Tolide-Ie HR. Intravitreal infliximab in experimental endotoxin-induced uveitis. Eur J Ophthalmol. 2009;19:818–823.
    1. Melo GB, Moraes Filho MN, Rodrigues EB, Regatieri CV, Dreyfuss JL, Penha FM, Pinheiro MM, Coimbra RC, Haapalainen EF, Farah ME. Toxicity and retinal penetration of infliximab in primates. Retina. 2012;32:606–612. doi: 10.1097/IAE.0b013e3182252a23.
    1. Rassi AR, Rigueiro MP, Isaac DL, Dourado L, Abud MB, Freitas EC, Carneiro LB, Avila MP. A safety study of retinal toxicity after serial intravitreal injections of infliximab in rabbits eyes. Arq Bras Oftalmol. 2011;74:352–356. doi: 10.1590/S0004-27492011000500009.
    1. Regatieri CV, Dreyfuss JL, Melo GB, Lavinsky D, Farah ME, Nader HB. Dual role of intravitreous infliximab in experimental choroidal neovascularization: effect on the expression of sulfated glycosaminoglycans. Invest Ophthalmol Vis Sci. 2009;50:5487–5494. doi: 10.1167/iovs.08-3171.
    1. Yuksel E, Hasanreisoglu B, Yuksel N, Yilmaz G, Ercin U, Bilgihan A. Comparison of acute effect of systemic versus intravitreal infliximab treatment in an experimental model of endotoxin-induced uveitis. J Ocul Pharmacol Ther. 2014;30:74–80. doi: 10.1089/jop.2012.0238.
    1. Beer PM, Wong SJ, Schartman JP, Kulas KE, Hartman CL, Giganti M, Falk NS. Infliximab stability after reconstitution, dilution, and storage under refrigeration. Retina. 2010;30:81–84. doi: 10.1097/IAE.0b013e3181b48fb4.
    1. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol. 2009;147:825–830. doi: 10.1016/j.ajo.2008.12.004.
    1. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade) Retina. 2010;30:71–80. doi: 10.1097/IAE.0b013e3181bcef3b.
    1. Arias L, Caminal JM, Badia MB, Rubio MJ, Catala J, Pujol O. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy. Retina. 2010;30:1601–1608. doi: 10.1097/IAE.0b013e3181e9f942.
    1. Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina. 2011;31:298–303. doi: 10.1097/IAE.0b013e3181eac7a6.
    1. Wu L, Arevalo JF, Hernandez-Bogantes E, Regatieri CV, Roca JA, Farah ME. Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group. J Ocul Pharmacol Ther. 2013;29:366–371. doi: 10.1089/jop.2012.0203.
    1. Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina. 2010;30:1530–1535. doi: 10.1097/IAE.0b013e3181d3758a.
    1. Farvardin M, Afarid M, Shahrzad S. Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther. 2012;28:628–631.
    1. Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol. 2012;154:534–541. doi: 10.1016/j.ajo.2012.03.035.
    1. Wu L, Arevalo JF, Hernandez-Bogantes E, Roca JA. Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group. Int Ophthalmol. 2012;32:235–243. doi: 10.1007/s10792-012-9559-8.
    1. Tsilimbaris M, Diakonis VF, Naoumidi I, Charisis S, Kritikos I, Chatzithanasis G, Papadaki T, Plainis S. Evaluation of potential retinal toxicity of adalimumab (Humira) Graefes Arch Clin Exp Ophthalmol. 2009;247:1119–1125. doi: 10.1007/s00417-009-1065-y.
    1. Lichtlen P, Lam TT, Nork TM, Streit T, Urech DM. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Invest Ophthalmol Vis Sci. 2010;51:4738–4745. doi: 10.1167/iovs.09-4890.
    1. Manzano RP, Peyman GA, Carvounis PE, Damico FM, Aguiar RG, Ioshimoto GL, Ventura DF, Cursino ST, Takahashi W. Toxicity of high-dose intravitreal adalimumab (Humira) in the rabbit. J Ocul Pharmacol Ther. 2011;27:327–331. doi: 10.1089/jop.2010.0174.
    1. Arevalo JF, Serrano MA, Wu L. Combined inhibition of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) for the treatment of macular edema of various etiologies: a short-term pilot study. Eye (Lond) 2013;27:569–571. doi: 10.1038/eye.2012.301.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa